BACKGROUND: @entity1817 ( @entity1817 ) has emerged as a potential alternative to routine axillary dissection in clinically node-negative @entity0 . STUDY DESIGN: From September 1995 to June 1996 at Memorial Sloan-Kettering Cancer Center, 60 @entity1 with clinically node-negative @entity5 underwent @entity1817 , which was immediately followed by standard axillary dissection. Both blue dye and radioisotope were used to identify the sentinel node. @entity1817 was compared with standard axillary dissection for its ability to accurately reflect the final pathologic status of the axillary nodes. RESULTS: The sentinel node was successfully identified by lymphoscintigraphy in 75% (42 of 56), by blue dye in 75% (44 of 59), by isotope in 88% (52 of 59), and by the combination of blue dye and isotope in 93% (55 of 59) of all 59 evaluable @entity1 . Of the 55 @entity1 in this study where sentinel nodes were identified, 20 (36%) were histologically positive. The sentinel node was falsely negative in three @entity1 , yielding an accuracy of 95%. @entity1817 was more accurate for T1 (98%) than for T2-T3 @entity5 (82%). CONCLUSIONS: Lymphatic mapping is technically feasible, reliably identifies a sentinel node in most cases, and appears more accurate for T1 @entity5 than for larger lesions. Blue dye and radioisotope are complementary techniques, and the overall success of the procedure is maximized when the two are used together.

Sentinel lymph node biopsy in XXXX : initial experience at Memorial Sloan-Kettering Cancer Center.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1817 :: ('MESH:D012804', 'Disease') :: ['SNB', 'Sentinel node biopsy'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'tumors'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']
@entity0 :: (MESH:D001943,Disease) :: ['breast cancer']
